stockrow
Friday 6 November 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
49.54
2.19
+4.63%
Follow SEPN
Alert me
Septerna, Inc. (SEPN) Return on equity
Septerna, Inc.'s return on equity over the twelve months to 30 June 2026 was −6.34%, up 5.8 percentage points from fiscal 2025 (−12.2%). That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −12.2% | 25.43 |
| FY2024 | −37.6% | (37.62) |
| FY2023 | 0.00% | — |
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| VCEL Vericel Corporation compare | 9.44% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| SEPN Septerna, Inc. | −6.34% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| ZYME Zymeworks Inc. compare | −72.3% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement